Partner Content Partner Content Launch Excellence 2020 In the past year, the competition in biosimilars and complex generics has complicated the launch landscape.
Views & Analysis Launch excellence in a disrupted world The accelerating speed of change within the pharmaceutical launch environment raises considerable challenges for launch excellence, as companies grapple with a complex and ever-changing wor
News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.